Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=44 Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Metastatic Gastric Cancer · Advanced Unresectable Gastric Cancer
Primary: The Proportion of Patients With Objective Response (Complete Response or Partial Response) — 0.409 Proportion of patients — p=0.0012
Phase 2 N=43 Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Esophageal Cancer
Primary: Overall Survival (1-year Rate Reported) — 71 percentage of participants
Phase 2 N=40 Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Gastric Cancer
Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants
Phase 2 N=39 FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Gastro-Esophageal Junction Adenocarcinoma · Gastric Cancer
Primary: Objective Response Rate — 15 Participants
Phase 2 N=58 Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
Stomach Cancer · Gastric Cancer
Primary: Complete Pathologic Response Rate — 14 percentage of participants
Phase 2 N=53 Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Gastric Cancer
Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders
Phase 2 N=38 Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
Unresectable Adenocarcinoma of the Esophagus · Metastatic Adenocarcinoma of the Esophagus · Unresectable Adenocarcinoma of Gastric Cardia
Primary: Overall Response Rate of Previously-untreated Patients With Unresectable or Metastatic Adenocarcinomas of the Upper Gastrointestinal Tract When Treated With the…
Phase 2 N=12 Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer
Primary: Comparison of Progression-free Survival — 6.1; 2.4 Months — p=0.43
Phase 2 N=39 Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach · Intestinal Adenocarcinoma of the Stomach
Primary: Response Rates (RR) in Metastatic Gastric/GE Junction Tumors — 2; 9; 3; 16 participants
Phase 2 N=202 S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer · Gastric Cancer
Primary: Progression-free Survival (PFS) in High-ERCC1 Patients — 4.7; 5.3 months — p=0.83
Phase 2 N=60 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Esophageal Neoplasms · Stomach Neoplasms · Neoplasm Metastasis
Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months
Phase 2 N=61 Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
Esophageal Cancer · Gastric Cancer
Primary: Feasibility of Induction Chemoradiotherapy as Measured by Resectability Rate — 54 Participants
Phase 2 N=98 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
Esophageal Cancer
Primary: Pathological Complete Response — 26 participants
Phase 2 N=67 Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer
Stomach Neoplasms · Esophageal Neoplasms
Primary: Number of Participants With an Objective Response — 25; 22 Participants
Phase 3 N=774 A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer
Adenocarcinoma
Primary: Overall Survival — 12.1; 10.1 months
Phase 2 N=62 Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer · Gastric Cancer
Primary: Percentage of Participants With Pathologic Complete Response (PCR) — 28.6; 40.7 percentage of participants
Phase 2 N=38 Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Esophageal Cancer · Stomach Cancer
Primary: 10-month Progression-Free Survival Rate — 40.0 probability (%)
Phase 2 N=34 Docetaxel and Epirubicin in Advanced Gastric Cancer
Stomach Neoplasms
Primary: Overall Survival — 13.4 month
Phase 2 N=40 Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric Cancer · Esophageal Neoplasms
Primary: Objective Response (Complete, Partial, Stable and Progression) — 0; 7; 22; 9 participants
Phase 2 N=35 Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Undifferentiated Carcinoma · Gastric Adenocarcinoma
Primary: Overall Response Rate — 26 percentage of participants
Phase 2 N=111 Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma · Gastric Cancer
Primary: 6 Month Progression Free Survival (PFS) — 63; 53; 73 percentage of paticipants
Phase 2 N=16 Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin
Esophageal Cancer · Gastric Cancer
Primary: Complete and Partial Response Rate — 0; 1; 4; 11 participants
Phase 2 N=40 Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Gastric Adenocarcinoma · Gastro-esophageal Junction Adenocarcinoma
Primary: Progression-free Survival (PFS) — 5.257 months
Phase 2 N=22 Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 · Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 · Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Primary: Number of Patients With a Pathologic Complete Response — 2 Participants
Phase 1 N=20 TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Gastric Adenocarcinoma · GastroEsophageal Cancer
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants
Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
Phase 2 N=43 Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Esophageal Cancer · Gastric Cancer · Neoplasm Metastasis
Primary: Overall Response Rate — 0.029 proportion of paticipants
Phase 2 N=39 Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Esophageal Cancer · Gastric Cancer
Primary: Time to Progression — 6.6 months
Phase 2 N=72 Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Percentage of Participants With Objective Response Assessed by Independent Review Committee — 31; 58 percentage of participants